Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies

Round 1

Reviewer 1 Report

This paper comprehensively reviews the development of precision dermatological science, with a focus on integrating molecular biomarkers into personalized treatment strategies for various skin diseases. It emphasizes the importance of specific biomarkers in the diagnosis, staging, and monitoring of diseases (such as pustular dermatosis, psoriasis, eczema, alopecia areata, vitiligo, and chronic spontaneous urticaria) and their role in guiding targeted therapy. The commentary highlights the success of biomarker-driven approaches in skin malignancies and the potential of emerging technologies such as artificial intelligence, nanotechnology, and multi-omics integration in advancing personalized dermatological care. I really like this article, but I have some opinions on it:

I wonder if could you write about Acne; acne is also a significant disease for us, with many articles on acne appearing recently. Most surprisingly, there has been a breakthrough in sebaceous gland experiments with acne. The differentiation trajectory of sebaceous glands in mice is becoming clearer (J Han, isciences, 2023), and the methodology is starting to be established. You could also add some content to layer over this section. In addition to WNT signals, AKT can also mediate β-catenin signal activation in Hair Follicle Stem Cells (HFSCs). Macrophages play an important role in this process. Injury promotes the production of the chemokine CCL2 by Hair Follicle (HF) keratinocytes, which in turn recruits macrophages. The number of macrophages increases during the HF growth phase and, among them, CX3CR1 bone marrow-derived macrophages secrete TNF and TGFβ1. TNF activates HFSCs through the AKT/ β-catenin signaling axis to induce wound-induced hair anagen cell re-entry/growth (WIHA) and wound-induced hair follicle neogenesis (WIHN). TGFβ1 signaling is essential for WIHA/ WIHN and may activate HF regeneration through the AKT/PI3K pathway. (Kobayashi, T. Immunity 2019)(Wang, X.; et al. 2017)(Rahmani, W. J. Investig. Dermatol. 2018)

For example, in psoriasis, elevated levels of interleukin-17 (IL-17) and tumor necrosis factor-alpha (TNF-alpha) have been implicated in disease pathogenesis, prompting the development of targeted biologic therapies that specifically inhibit these cytokines. My suggestion is to rephrase it to: "Many skin diseases involve pathways such as the elevated levels of interleukin-17 (IL-17) and tumor necrosis factor-alpha (TNF-alpha) induced pathway like AKT/beta-catenin implicated in disease pathogenesis" (Haiyan Chen, Plos one, 2017)(H Chen,Theranostics,2019)(Han, Frontiers in cell development,2021). This prompts the development of targeted biologic therapies that specifically inhibit these cytokines. Moreover, it is best to cite references in the Introduction section.

Minor editing of English language required

Author Response

Thank you so much for the feedback. We appreciate your time and consideration. Regarding the changes made:

• We have added a section on the biomarkers of acne and the pathways associated with its pathogenesis, and included this information in the corresponding table. 
• We have also rephrased the suggested sentence, and added additional citations in the introduction as well. 

Reviewer 2 Report

 A nice work on  Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies. Biomarkers in personalized dermatological treatments represent a significant ad-vancement, offering tailored approaches to patient care.  Good work.

Overall, it is a good paper on biomarkers in biological drugs. It adds information on the use of biomarkers to choose the correct biological drug, since a few information there are in the literature on biomarkers. The references are appropriate? No additional comments on the tables and figures and
quality of the data.

It would be great if you could add a section on the formation of anti-drug antibodies ( for explample  anti body anti infliximab)

Author Response

• We have added a section on anti-drug antibodies before the discussion of personalized therapies, including anti-infliximab. 

Round 2

Reviewer 1 Report

Congratulation! Article is ready for publication.